Novartis chief sees sales dip until mid-2013

October 7, 2012

Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013.

The fall in sales of the company's best-selling drug was "significant" in the United States since the end of September, when the patent ended, chief executive Joseph Jimenez told Swiss weekly SonntagsZeitung.

Sales of competing generic equivalents to the Novartis drug already caused a $2-billion (1.5-billion-euro) drop in demand for Diovan, which registered sales of $6 billion in a single year, the report added.

Rejecting the need for a fresh swathe of to counter the expected in the next three quarters, Jimenez said he planned to pursue a series of smaller measures instead.

The Basel-based company already cut 2,000 positions in late 2011, mainly in Switzerland and the US, and announced in January 2012 it was further downsizing its American operation by shedding another 1,630 positions.

Jimenez also said in the interview that the group had reviewed its range of products and expected a major rise in sales in the second half of 2013.

The patent for Diovan expired in Europe at the end of last year for Novartis, which employs around 100,000 people worldwide, according to its website.

Explore further: New drugs shore up Novartis in Q2

Related Stories

New drugs shore up Novartis in Q2

July 19, 2012
(AP) — Swiss pharmaceutical company Novartis AG reported a net profit of $2.73 billion during the second quarter, as new drugs and acquisitions offset patent expirations, lower sales of generic medicines and the strengthening ...

NGOs protest Novartis' Glivec patent quest in India

February 23, 2012
Several NGOs protested Thursday at the annual meeting of Novartis against the attempt by the Swiss pharmaceutical group's India company to obtain a patent for its anti-cancer drug Glivec.

Novartis announces 2,000 job losses, profits up

October 25, 2011
Swiss pharmaceutical giant Novartis announced 2,000 job losses Tuesday, mostly in Switzerland and the United States, while reporting net profits of $3.53 billion (2.5 billion euros) for the third quarter.

Novartis says EU approves expanded use of Glivec

February 27, 2012
Swiss pharmaceutical group Novartis said Monday the European Union will allow it to expand its use of the drug Glivec to treat certain rare forms of gastrointestinal cancer.

India generics giant wins cancer drug patent case

September 8, 2012
Indian generics giant Cipla says it has scored a "landmark" court win in a patent challenge launched by Switzerland's Roche Holding over the Mumbai firm's version of a lung-cancer drug.

Recommended for you

Glucocorticoids offer long-term benefits for patients with Duchenne muscular dystrophy

November 22, 2017
Glucocorticoids, a class of steroid hormone medications often prescribed to patients with Duchenne muscular dystrophy (DMD), offer long-term benefits for this disease, including longer preservation of muscle strength and ...

Baby-boomers and millennials more afflicted by the opioid epidemic

November 21, 2017
Baby-boomers, those born between 1947 and 1964, experienced an excess risk of prescription opioid overdose death and heroin overdose death, according to latest research at Columbia University's Mailman School of Public Health. ...

Sensor-equipped pill raises technological, ethical questions

November 17, 2017
The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients ...

New painkillers reduce overdose risk

November 16, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed new opioid pain relievers that reduce pain on par with morphine but do not slow or stop breathing—the cause of opiate overdose.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.